Indications |
Oral Allergic and inflammatory disorders Adult: 4-48 mg daily. Nasal Treatment and prophylaxis of allergic rhinitis Adult: As acetonide: Initially, 2 sprays (110 mcg) into each nostril once daily, reduced to 1 spray (55 mcg) when under control. Child: 6-12 yr: as acetonide: 1 spray (55 mcg) into each nostril once daily. Increased to 220 mcg daily in severe cases. Intramuscular Suppression of allergic and inflammatory disorders Adult: As acetonide: 20-80 mg via deep IM into gluteal muscles. As diacetate: 40 mg inj. Child: As acetonide: deep IM into gluteal muscle: initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses. Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol. Intramuscular Symptomatic control for hay fever Adult: As acetonide: 40-100 mg via deep IM into gluteal muscles. As diacetate: 40 mg wkly. Child: As acetonide: deep IM into gluteal muscle: initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses. Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol. Intra-articular Inflammatory joint diseases Adult: As acetonide: Smaller joints: 2.5-5 mg (up to 10 mg), larger joints: 5-15 mg (up to 40 mg). Max: 20-80 mg/treatment. As hexacetonide: Initial: 2-20 mg/day. Intradermal Inflammatory skin conditions Adult: As acetonide: 1-3 mg/site. Max: 30 mg in total if several sites of inj used. As diacetate: 5 mg in divided doses for small lesions or up to 48 mg in divided doses for large lesions. Max: 12.5 mg/inj site. Max: 25 mg/lesion. As hexacetonide: max 500 mcg per square inch or 80 mcg/cm2 of affected skin. Mouth/Throat Mouth ulceration Adult: A small amount (about 0.6 cm) of the 0.1% paste is pressed onto the lesion without rubbing until a thin film develops. Apply 2 or 3 times daily, preferably after meals. Re-evaluate if recovery does not occur after 7 days of treatment. Topical/Cutaneous Inflammatory skin conditions Adult: As acetonide: Apply a 0.025-0.5% cream/lotion/ointment sparingly onto affected area 2-3 times daily. Lower concentrations may be used up to 4 times daily. |
Contraindications |
Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates (Parenteral) |
Warnings / Precautions |
Diabetes; hypertension, renal and liver impairment; glaucoma; psychosis; delayed tissue healing; cirrhosis; heart failure; recent MI; hypothyroidism; osteoporosis; peptic ulceration; thromboembolic disorders. Monitor height in children on prolonged therapy. Avoid rapid drug withdrawal. Elderly, children, pregnancy, lactation. |
Adverse Reactions |
HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing. Potentially Fatal: Acute adrenal insufficiency may be precipitated by infection or trauma in patients on long-term corticosteroid therapy or rapid withdrawal. |
Drug Interactions |
Lowering of plasma salicylates levels. Increased risk of GI bleeding and ulceration with NSAIDs. Antagonised blood glucose-lowering effects of the antidiabetics. Increased risk of hyperkalaemia with amphotericin B, β agonists, β-blockers, potassium-depleting diuretics, theophylline. Increased clearance of the triamcinolone with ciclosporin, carbamazepine, phenytoin, barbiturate, rifampicin. Infections may develop if given with live vaccines. See Below for More triamcinolone Drug Interactions |
Mechanism of Actions |
Triamcinolone has mainly glucocorticoid activity. It suppresses the migration of polymorphonuclear leukocytes and reduces capillary permeability thereby decreasing inflammation. Absorption: Absorbed systemically (topical). Distribution: Crosses the placenta. Protein-binding: Plasma albumin (much smaller extent than hydrocortisone). Excretion: Elimination half-life: 2-5 hr (plasma). |
Administration |
Should be taken with food. |
Storage Conditions |
Intra-articular: Store between 20-25°C (68-77°F). Intradermal: Store between 20-25°C (68-77°F). Intramuscular: Store between 20-25°C (68-77°F). Topical/Cutaneous: Store between 15-30°C. |
ATC Classification |
D07AB09 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases. D07XB02 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases. H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations. A01AC01 - triamcinolone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth. R01AD11 - triamcinolone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis. R03BA06 - triamcinolone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids. S01BA05 - triamcinolone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye. |
Storage |
Intra-articular: Store between 20-25°C (68-77°F). Intradermal: Store between 20-25°C (68-77°F). Intramuscular: Store between 20-25°C (68-77°F). Topical/Cutaneous: Store between 15-30°C. |
Available As |
|
Triamcinolone
Post Review about Triamcinolone Click here to cancel reply.
Triamcinolone Containing Brands
Triamcinolone is used in following diseases
Drug - Drug Interactions of Triamcinolone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.